As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast cancer patients may be considered…
Toronto, Ontario, Jan. 21, 2025 (GLOBE NEWSWIRE) -- LifeLabs is proud to announce that it has been named Canada’s Most…
PARSIPPANY, NJ, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX:…
November 03, 2024 17:03 ET | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals…